Alector ALEC Stock
Alector Price Chart
Alector ALEC Financial and Trading Overview
| Alector stock price | 1.51 USD |
| Previous Close | 1.64 USD |
| Open | 1.64 USD |
| Bid | 1.18 USD x 200 |
| Ask | 1.89 USD x 200 |
| Day's Range | 1.48 - 1.64 USD |
| 52 Week Range | 1.09 - 3.4 USD |
| Volume | 518.71K USD |
| Avg. Volume | 710.25K USD |
| Market Cap | 178.75M USD |
| Beta (5Y Monthly) | 0.599 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.1 USD |
ALEC Valuation Measures
| Enterprise Value | 6.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.3 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 9.705736 |
| Price/Book (mrq) | 17.12766 |
| Enterprise Value/Revenue | 0.368 |
| Enterprise Value/EBITDA | -0.053 |
Trading Information
Alector Stock Price History
| Beta (5Y Monthly) | 0.599 |
| 52-Week Change | -3.59% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 3.4 USD |
| 52 Week Low | 1.09 USD |
| 50-Day Moving Average | 1.98 USD |
| 200-Day Moving Average | 2 USD |
ALEC Share Statistics
| Avg. Volume (3 month) | 710.25K USD |
| Avg. Daily Volume (10-Days) | 859.64K USD |
| Shares Outstanding | 111.03M |
| Float | 93.8M |
| Short Ratio | 5.79 |
| % Held by Insiders | 9.66% |
| % Held by Institutions | 82.19% |
| Shares Short | 5.72M |
| Short % of Float | 5.45% |
| Short % of Shares Outstanding | 5.14% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2382.31% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.70% |
| Return on Equity (ttm) | -238.85% |
Income Statement
| Revenue (ttm) | 18.42M USD |
| Revenue Per Share (ttm) | 0.17 USD |
| Quarterly Revenue Growth (yoy) | -71.50% |
| Gross Profit (ttm) | -88864000 USD |
| EBITDA | -127494000 USD |
| Net Income Avi to Common (ttm) | -125388000 USD |
| Diluted EPS (ttm) | -1.19 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 206.52M USD |
| Total Cash Per Share (mrq) | 1.86 USD |
| Total Debt (mrq) | 34.55M USD |
| Total Debt/Equity (mrq) | 332.77 USD |
| Current Ratio (mrq) | 5.25 |
| Book Value Per Share (mrq) | 0.094 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -173060992 USD |
| Levered Free Cash Flow (ttm) | -119106128 USD |
Profile of Alector
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 131 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 415 231 5660 |
| Website | https://www.alector.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 103 |
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Q&A For Alector Stock
What is a current ALEC stock price?
Alector ALEC stock price today per share is 1.51 USD.
How to purchase Alector stock?
You can buy ALEC shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alector?
The stock symbol or ticker of Alector is ALEC.
Which industry does the Alector company belong to?
The Alector industry is Biotechnology.
How many shares does Alector have in circulation?
The max supply of Alector shares is 111.03M.
What is Alector Price to Earnings Ratio (PE Ratio)?
Alector PE Ratio is now.
What was Alector earnings per share over the trailing 12 months (TTM)?
Alector EPS is -1.19 USD over the trailing 12 months.
Which sector does the Alector company belong to?
The Alector sector is Healthcare.
Alector ALEC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25873.18 USD — |
-1.55
|
6.31B USD — | 25822.1 USD — | 26139.37 USD — | — - | 6.31B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12700.6 USD — |
-1.53
|
— — | 12675.61 USD — | 12830.27 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6546.6 USD — |
-1.47
|
— — | 6508.46 USD — | 6585.47 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1254.95 USD — |
-1.05
|
— — | 1250.11 USD — | 1262.34 USD — | — - | — — |
- {{ link.label }} {{link}}